Literature DB >> 24222275

Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1.

Dan Ilkovitch1, Roberto Carrio, Diana M Lopez.   

Abstract

Mucin 1 (MUC1) is a polymorphic type 1 transmembrane protein found on the apical surface of normal cells lining the lumen of ducts and glands. Mucins are thought to provide mucosal protection from environmental exposures and carcinogens. An altered form of the MUC1 glycoprotein, which is hypoglycosylated, is expressed in several types of human cancers. In our laboratory, we have found that transfection of a murine mammary tumor cell line with a human secreted isoform of MUC1 rendered these DA-3 cells (DA-3/sec) incapable of growing in intact BALB/c mice. In contrast, implantation of DA-3 cells transfected with the human transmembrane isoform of MUC1 (DA-3/TM), resulted in tumor formation and ultimately death of the animals, similar to the DA-3 parental line. Importantly, inoculation of the DA-3/sec cells in immunodeficient nude mice resulted in tumor formation, indicating that the MUC1/sec molecule's antitumor activity is immunologically controlled. In this review, we summarize the studies we have performed to elucidate possible mechanisms for the immune-mediated antitumor effect of MUC1/sec and/or a unique peptide present in this mucin. Understanding these mechanisms may provide new immunotherapeutic approaches that could be used to target different types of cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24222275     DOI: 10.1007/s12026-013-8451-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  129 in total

1.  Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen.

Authors:  O Akbari; R H DeKruyff; D T Umetsu
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

2.  Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells.

Authors:  K O Lloyd; J Burchell; V Kudryashov; B W Yin; J Taylor-Papadimitriou
Journal:  J Biol Chem       Date:  1996-12-27       Impact factor: 5.157

Review 3.  Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas.

Authors:  Olivera J Finn; Kira R Gantt; Andrew J Lepisto; Sharmila Pejawar-Gaddy; Jia Xue; Pamela L Beatty
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

4.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

5.  In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.

Authors:  Hiroshi Nagai; Tatsuya Horikawa; Isao Hara; Atsushi Fukunaga; Shuntaro Oniki; Masahiro Oka; Chikako Nishigori; Masamitsu Ichihashi
Journal:  Exp Dermatol       Date:  2004-10       Impact factor: 3.960

6.  Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.

Authors:  Amit Gupta; Yair Lotan; Raheela Ashfaq; Claus G Roehrborn; Ganesh V Raj; Corinne C Aragaki; Francesco Montorsi; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2008-06-23       Impact factor: 20.096

7.  MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2.

Authors:  Joseph F Grosso; Lynn M Herbert; Jennifer L Owen; Diana M Lopez
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

8.  High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.

Authors:  Paolo Serafini; Rebecca Carbley; Kimberly A Noonan; Gladys Tan; Vincenzo Bronte; Ivan Borrello
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

9.  Increased expression of MUC1 in advanced pancreatic cancer.

Authors:  Yuji Hinoda; Yoshito Ikematsu; Michiko Horinochi; Shuji Sato; Kotaro Yamamoto; Tomoko Nakano; Mikiko Fukui; Yutaka Suehiro; Yuichiro Hamanaka; Yoshiro Nishikawa; Hideo Kida; Shinji Waki; Masaaki Oka; Kohzoh Imai; Suguru Yonezawa
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

10.  Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration.

Authors:  Elzbieta Pluskota; Dmitry A Soloviev; Edward F Plow
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

View more
  3 in total

Review 1.  Genetic variants of mucins: unexplored conundrum.

Authors:  Sushil Kumar; Eric Cruz; Suhasini Joshi; Asish Patel; Rahat Jahan; Surinder K Batra; Maneesh Jain
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

Review 2.  MUC1: Structure, Function, and Clinic Application in Epithelial Cancers.

Authors:  Wenqing Chen; Zhu Zhang; Shiqing Zhang; Peili Zhu; Joshua Ka-Shun Ko; Ken Kin-Lam Yung
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

3.  Tumour biomarkers: association with heart failure outcomes.

Authors:  C Shi; H H van der Wal; H H W Silljé; M M Dokter; F van den Berg; L Huizinga; M Vriesema; J Post; S D Anker; J G Cleland; L L Ng; N J Samani; K Dickstein; F Zannad; C C Lang; P L van Haelst; J A Gietema; M Metra; P Ameri; M Canepa; D J van Veldhuisen; A A Voors; R A de Boer
Journal:  J Intern Med       Date:  2020-05-05       Impact factor: 8.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.